跳至主要内容
临床试验/NCT06683378
NCT06683378招募中1 期

Phase I Randomized, Double-blind Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Nucleus Basalis of Meynert or Substantia Nigra for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery

Craig van Horne, MD, PhD2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2025年7月21日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
24
试验地点
2
主要终点
Successful deployment of bilateral peripheral nerve tissue (PNT) into the brain

研究概览

简要总结

The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
45 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Undergoing DBS
  • Diagnosis of clinically established or clinically probably PD as defined by MDS criteria
  • Age 45-75, inclusive
  • Able to tolerate the surgical procedure
  • Able to undergo all planned assessments
  • Available access to the sural nerve

排除标准

  • Any condition that would not make the subject a candidate for DBS
  • Dementia diagnosis
  • Previous PD surgery or intracranial surgery
  • Unable to undergo an MRI
  • An obstructed trajectory path to the substantia nigra and nucleus basalis of Meynert

研究组 & 干预措施

Peripheral nerve tissue (PNT) deployment to the Substantia Nigra

Active Comparator

干预措施: Reparative Autologous peripheral nerve tissue (Procedure)

Peripheral nerve tissue (PNT) deployment to the nucleus basalis of Meynert

Active Comparator

干预措施: Reparative Autologous peripheral nerve tissue (Procedure)

结局指标

主要结局

Successful deployment of bilateral peripheral nerve tissue (PNT) into the brain

时间窗: Intraoperative

Number of participants in each study arm who successfully receive bilateral PNT delivery.

Number of participants completing 12 month study visit

时间窗: 12-month study visit

Total number of participants to complete study visit by arm assignment

Study-related adverse events as assessed by MedDRA v27

时间窗: Enrollment to 24-month study visit

Total number of study-related adverse events experienced by participants.

Study-related serious adverse events as assessed by MedDRA v.27

时间窗: Enrollment to 24-month study visit

Total number of serious adverse events experienced by participants

次要结局

  • PNT deployment attempts(During surgery)
  • Mean change in Montreal Cognitive Assessment (MoCA) scores(Baseline 6, 12 and 24 months after surgery)
  • Mean change in Neuropsychological assessment scores(Baseline, 12 and 24 months)
  • Change in Neuropsychological diagnosis(Baseline, 12 and 24 months)
  • Change in Neuropsychological domains with impairment(At 12, 24 months compared to baseline)
  • Mean change in Modified Schwab and England Scale of Activities of Daily Living scores(At 6, 12, 24 months compared to baseline)
  • Mean change in Parkinson's Disease Questionnaire-8 (PDQ-8) quality of life scores(At 12 and 24 months compared to baseline)
  • Mean change in Non-motor symptom scale scores(At 12 and 24 months compared to baseline)
  • Mean change of the Movement Disorder Society - Unified Parkinsons Disease Rating Scale (MDS-UPDRS) Part I scores(6, 12, and 24 months as compared to baseline)
  • Mean change of the MDS-UPDRS Part II scores(At 6, 12, 24 months compared to baseline)
  • Mean change in MDS-UPDRS Part III scores(At 6, 12, 24 months compared to baseline)
  • Mean change in MDS-UPDRS Part IV scores(At 6, 12, and 24 months compared to baseline)
  • Number of participants completing 24-month study visit(24-month study visit)
  • Mean change in Dementia Rating Scale (DSRS)(Baseline 6, 12 and 24 months after surgery)

研究者

发起方
Craig van Horne, MD, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Craig van Horne, MD, PhD

Department of Neurosurgery Chair

University of Kentucky

研究点 (2)

Loading locations...

相似试验

A Study to Evaluate Feasibility, Safety, and... | 临床试验